Abstracts tagged "immunology"

Abstract Number: 1749 • ACR Convergence 2022
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
Eddie James¹, Cliff Rims², Sylvia Posso², Jeffrey Carlin³, William Kwok², Shao-En Ong⁴ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 1095 • ACR Convergence 2022
A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Bahram Razani¹, Jared Liu¹, Ryan Tobias¹, Sugandh Kumar¹, Zhi-Ming Huang¹, Wilson Liao², Barbara Malynn³ and Averil Ma³, ¹Dept. of Dermatology, UCSF, San Francisco, ²Dept. of Dermatology, San Francisco, ³Division of Gastroenterology, UCSF, San Francisco
Background/Purpose: A20 (Tnfaip3) levels are reduced in psoriatic plaques and polymorphisms in the TNFAIP3 gene locus are associated with increased risk for both psoriasis and psoriatic…
Abstract Number: 1698 • ACR Convergence 2022
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
Daniel Rios¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Shradha Rao¹, Jess Floro¹, Joelle Baddour¹, Nisha Perez², Greg Bisacchi², Oliver Saunders², Donna Romero¹, Menachem Fromer², Enrique Garcia-Rivera², Wilson McKerrow², Julie Behr², Bryan Thornlow², Dennis Zaller², David Proia² and Wenyan Miao², ¹Rome Therapeutics, Cambridge, MA, ²Rome Tx, Cambridge, MA
Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
Abstract Number: 1762 • ACR Convergence 2022
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
Mark Rudolph, Rory Bloch, Anja Kammesheidt and Roberta Alexander, Exagen, Inc., Vista, CA
Background/Purpose: COVID-19 can cause autoantibody signatures in severely ill patients, and widespread emerging post-acute sequelae of SARS-CoV-2 (PASC) share many symptoms consistent with rheumatologic involvement…
Abstract Number: 0012 • ACR Convergence 2022
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
Merri-Grace Allred and Scott Lieberman, University of Iowa, Iowa City, IA
Background/Purpose: Sjogren's disease is a chronic autoimmune disease autoimmune disease characterized by foci of inflammation of the lacrimal and salivary glands. As disease progresses, B…
Abstract Number: 0558 • ACR Convergence 2022
Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation
Brianne Barker¹, Megan Hanlon², Siobhan Wade¹, Douglas Veale³, Ursula Fearon¹ and Mary Canavan⁴, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology, Dublin, Ireland, ³St. Vincent's University Hospital, Blackrock, Dublin, Ireland, ⁴Trinity College, Dublin, Ireland
Background/Purpose: mTOR is a metabolic master regulator of both innate and adaptive immunity, however its exact role in synovial fibroblasts is unknown. RA synovial fibroblasts…
Abstract Number: 0752 • ACR Convergence 2022
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
Rui Chen¹, Yu Xia², Baiyong Li², Xiang Ni², Guoqin Wang², Cui Zhang², Benchao Chen², Li Wang² and Hongzhong Jin³, ¹Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Akeso Biopharma, Inc., Zhongshan, China, ³Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Disease, Beijing, China
Background/Purpose: Interleukin-12 (IL-12) and interleukin-23 (IL-23) are two essential cytokins involved in the immune-mediated inflammatory disorders of psoriasis. Anti-IL-12/IL-23 therapy has been developed for the…
Abstract Number: 1164 • ACR Convergence 2022
Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
Judith Rademacher¹, Katharina Deschler², Sonja Lacher², Alina Huth², Markus Utzt², Stefan Krebs², Helmut Blum², Eduardo Beltrán², Klaus Dornmair² and Denis Poddubnyy³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU Munich, Munich, Germany, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Spondyloarthritis (SpA) is strongly associated with HLA-B27. The arthritogenic antigen hypothesis assumes the existence of specific peptides presented by risk-conferring HLA-B27 alleles to antigen-specific…
Abstract Number: 1701 • ACR Convergence 2022
High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
Patricia Pontes Aires¹, André Cunha¹, DANIELA GERENT PETRY PIOTTO¹, Maria Teresa Terreri² and Sandro Perazzio¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidad Federal São Paulo, São Paulo, Brazil
Background/Purpose: A20 haploinsufficiency (A20HA), an important monogenic etiology of Behçet's disease (BD), is caused by loss-of-function mutations in TNFAIP3. Although monocytes play an important role…
Abstract Number: 1763 • ACR Convergence 2022
Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica¹, Arturo Blazquez-Navarro², Jan Sokolar³, Moritz Anft⁴, Uta Kiltz⁵, Stephanie Pfaender⁶, Elena Vidal Blanco⁷, Timm Westhoff⁸, Nina Babel⁸, Ulrik Stervbo⁹ and Xenofon Baraliakos¹⁰, ¹Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin Center for Advanced Therapies, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr Universität Bochum, Herne, Germany, ⁴Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universit t Bochum, Medical Department I, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ⁷Ruhr-University Bochum, Department of Molecular and Medical Virology, Bochum, Germany, ⁸Marienhospital Herne, Ruhr-University Bochum, Herne, Germany, ⁹Marienhospital Herne - Klinik Mitte Medizinische Klinik I - Gastroenterologie, Nieren- und Hochdruckkrankheiten, Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Herne and Ruhr-Universität Bochum, Medical Department I, Bochum, Germany, ¹⁰Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate…
Abstract Number: 0015 • ACR Convergence 2022
Differential Antigen Binding of Closely Related Monoclonal ACPA
Caroline Grönwall¹, Anatoly Dubnovitsky¹, Philip Titcombe², Daniel Mueller² and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a hallmark of rheumatoid arthritis (RA) and the clonality and antigen targets of ACPA positive B cells can be…
Abstract Number: 0568 • ACR Convergence 2022
The Absence of Blk Leads to Increased Inflammation in a Murine Model of Kawasaki Disease
Melissa Kleinau¹, Mohammed Massumi², Lysa Langevin², Paul Tsoukas², Harper Cheng², Suzanne Tam², Trang Duong² and Rae Yeung³, ¹University of Toronto, Toronto, ON, Canada, ²Peter Gilgan Centre for Research and Learning, Toronto, ON, Canada, ³The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is the leading cause of acquired heart disease in children in developed countries characterized by inflammation of the coronary arteries leading…
Abstract Number: 0755 • ACR Convergence 2022
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Zesheng An¹, Xian Zhou¹, Yanfeng Li¹, Jane Jaquith¹, Kathleen McCarthy-Fruin¹, Kenneth J. Warrington¹, Ali Duarte-Garcia¹, Uma Thanarajasingam¹, Cornelia M. Weyand² and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA
Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].